1 In the present study we evaluated the receptor selectivity of the potent histamine H3 receptor antagonist, iodophenpropit (IPP) in comparison with the prototype antagonist, thioperamide. 2 IPP proved to be a potent competitive H3 receptor antagonist as measured against (R)-amethylhistamine-induced inhibition of electrically-evoked contractions of the guinea-pig jejunum (pA2=9.12+0.06, Schild slope: 1.0 0.1, n=8). In the same assay, thioperamide was slightly less potent (pA2 = 8.9 ± 0.2). histamine or the H3 receptor agonist, (R)-a-methylhistamine showed no affinity for the 5-HT3 receptor. 7 In the guinea-pig isolated ileum, imetit evoked concentration-dependent contractions, resulting in a pD2 value of 4.72 ± 0.03 (n = 9). The contractions were antagonized by ondansetron, yielding a pA2 value of 7.1 ± 0.1 (n = 9). Similarly ondansetron antagonized the contractions evoked by the 5-HT3 receptor agonist, 2-methyl-5-HT with a pA2 value of 7.3 ± 0.1 (n = 4). IPP and thioperamide did not mimic 2-methyl-5-HT but non-competitively inhibited the 2-methyl-5-HT-induced contractions of this preparation. 8 In an in vivo model for 5-HT3 activity, the Von Bezold Jarisch reflex, thioperamide showed antagonism in low dosages, which correlated well with the affinity for the 5-HT3 receptor site. Yet, at higher dosages no further 5-HT3 receptor antagonism was observed. For IPP no 5-HT3 receptor activity could be observed in vivo. 9 In the present study we showed that many H3 receptor compounds, that are regarded as highly selective (including the prototype drug, thioperamide), also interact with the 5-HT3 receptor, albeit at higher drug concentrations.